Navigation Links
Synthetic Biologics to Host Multiple Sclerosis-Estriol Investor Day in New York City on June 25, 2013
Date:6/13/2013

ROCKVILLE, Md., June 13, 2013 /PRNewswire/ -- Synthetic Biologics, Inc. (NYSE MKT: SYN), a developer of biologics focused on the prevention and treatment of serious infectious diseases, announced today that it will host a Multiple Sclerosis-Estriol Investor Day on Tuesday, June 25, 2013 from 9:00 a.m. to 11:00 a.m. at the InterContinental New York Barclay Hotel in New York City. This event will be accessible via a live webcast through the following internet link, https://viavid.webcasts.com/starthere.jsp?ei=1018556

Keynote speaker, Rhonda R. Voskuhl, M.D., will join Synthetic Biologics' executive management remotely for the presentations. Dr. Voskuhl is Professor, Department of Neurology, Jack H. Skirball Chair in Multiple Sclerosis Research and Director, Multiple Sclerosis Program at UCLA School of Medicine, and the lead investigator of the Phase II clinical trial evaluating the Company's oral estriol product candidate, Trimesta™, for the treatment of relapsing-remitting multiple sclerosis (MS). An overview of MS and the current market, as well as the history of estriol and its role in the treatment of MS will be discussed.

About Synthetic Biologics, Inc.

Synthetic Biologics, Inc. (NYSE MKT: SYN) is a biotechnology company focused on the development of biologics for the prevention and treatment of serious infectious diseases. The Company is developing an oral enzyme for the prevention of C. difficile infections, and a series of monoclonal antibody therapies for the treatment of Pertussis and Acinetobacter infections. In addition, the Company is developing a drug candidate for the treatment of relapsing-remitting multiple sclerosis and cognitive dysfunction in multiple sclerosis. For more information, please visit Synthetic Biologics' website at www.syntheticbiologics.com.

To download Synthetic Biologics' investor relations mobile device app, which allows users access to the Company's SEC documents, press releases and events, please click on the following links to download the IRapp on your iPhone and iPad or your Android mobile device.


'/>"/>
SOURCE Synthetic Biologics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Research Team Publishes New Methods for Synthetic Generation of Influenza Vaccines
2. Synthetic Biologics Reports First Quarter 2013 Financial Results
3. Peripheral Vascular Devices Market (Peripheral Vascular Stents, PTA Balloon Catheters, Guidewires, IVC Filters, Atherectomy, Chronic Total Occlusion, Embolic Protection Devices, Synthetic Surgical Grafts, Aortic Stents) - Global Industry Analysis, S
4. Details of New Synthetic Vaccine for Emerging H7N9 Threat Revealed at BIO International Convention in Chicago, April 22-25
5. Synthetic Biologics Reports Year End 2012 Financial Results
6. What Will Thermo Fisher Scientific and Life Technologies $14 billion Merger hold for the Top Ten Suppliers of Synthetic Biology Technology and DNA Sequencing Landscape?
7. Synthetic Biologics to Present at the 25th Annual ROTH Conference
8. Synthetic Biologics Reports that Flupirtine Sublicensee, Meda AB, to Initiate Phase II Fibromyalgia Clinical Trial in U.S.
9. Inovios Synthetic Flu Vaccine Doubles Rate of Elderly Subjects Displaying Protective Immune Responses
10. Synthetic Biologics Closes Deal for Acquisition of C. difficile Infectious Disease Program
11. Inovio Expands Synthetic Vaccine Intellectual Property License With University of Pennsylvania
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/25/2017)...  EpiVax, Inc., a leader in the fields ... announced the launch of EpiVax Oncology Inc., a ... cancer vaccines. EpiVax has provided $500,000 in seed ... technologies to the new precision immunotherapy venture. Gad ... as Chief Executive Officer. Gad brings over 25 ...
(Date:9/19/2017)... --  ZirMed Inc ., a recognized leader in cloud-based revenue ... been ranked #1 by its users for the seventh consecutive ... Survey. ZirMed was recognized as the top-ranked end-to-end revenue cycle ... over 200 beds and holds one of the longest #1 ... ...
(Date:9/12/2017)... MOUNTAIN LAKES, N.J. , Sept. 12, 2017  Consumer reviews ... Embrace Hearing as the number one company for hearing ... Oticon™, ReSound™ and fifteen other brands. ... Embrace Hearing Named #1 by Consumers For Hearing Aids ... Embrace Hearing is an online store that ...
Breaking Medicine Technology:
(Date:10/13/2017)... NY (PRWEB) , ... October 13, 2017 , ... Ellevate ... people in business to advocate for action towards gender equality at their inaugural Summit ... from around the globe, and reached a social audience of over 3 million. To ...
(Date:10/13/2017)... , ... October 13, 2017 , ... Yisrayl Hawkins, Pastor ... that explains one of the most popular and least understood books in the Holy ... and puzzling descriptions that have baffled scholars for centuries. Many have tossed it off ...
(Date:10/13/2017)... ... 2017 , ... Coveros, a leader in agile coaching services ... by the Center for Medicare and Medicaid Services (CMS). The Enterprise Agile Transformation ... Agile methodologies in a consistent and high value manner across CMS programs. Coveros ...
(Date:10/13/2017)... ... ... “America On The Brink”: the Christian history of the United States and the ... published author, William Nowers. Captain Nowers and his wife, Millie, have six children, ... in the Navy. Following his career as a naval aviator and carrier pilot, ...
(Date:10/12/2017)... ... 12, 2017 , ... CitiDent and San Francisco dentists, Dr. ... Oventus O2Vent technology. As many as 18 million Americans are estimated to suffer ... Oral appliances can offer significant relief to about 75 percent of people with ...
Breaking Medicine News(10 mins):